MeSH term | MeSH ID | Detail |
---|---|---|
Abortion, Spontaneous | D000022 | 12 associated lipids |
Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wakasugi H et al. | Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. | 1998 | Clin. Pharmacol. Ther. | pmid:9695727 |
Hashimoto Y | [Eradication therapies for Helicobacter pylori]. | 1998 | Kansenshogaku Zasshi | pmid:9695480 |
Habu Y et al. | Triple therapy with omeprazole, amoxicillin and clarithromycin is effective against Helicobacter pylori infection in gastric ulcer patients as well as in duodenal ulcer patients. Results of a randomized controlled trial in Japan. | 1998 Jul-Aug | Digestion | pmid:9693202 |
Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
Catalano F et al. | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692702 |
Bardhan KD et al. | Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692693 |
Soepandi P et al. | The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. | 1998 | Respirology | pmid:9692520 |
Bigard MA et al. | One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9690730 |
Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
Martin SJ and Pendland SL | Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. | 1998 | J. Antimicrob. Chemother. | pmid:9687103 |
Bordet AL et al. | [Mycobacterium chelonae cutaneous infection: efficacy of prolonged treatment by clarithromycin]. | 1997 | Ann Dermatol Venereol | pmid:9686059 |
Tonai A et al. | [Clarithromycin suppression of DNA synthesis by rat nasal mucosal cells enhanced by endotoxin instillation]. | 1997 | Jpn J Antibiot | pmid:9678983 |
Grübel P and Cave DR | Factors affecting solubility and penetration of clarithromycin through gastric mucus. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678818 |
Ahuja V et al. | Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678815 |
Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
Perri F et al. | Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. | 1998 | Ital J Gastroenterol Hepatol | pmid:9675647 |
Dunne EF et al. | Streptomyces pneumonia in a patient with human immunodeficiency virus infection: case report and review of the literature on invasive streptomyces infections. | 1998 | Clin. Infect. Dis. | pmid:9675460 |
Dore MP et al. | Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. | 1998 | Clin. Infect. Dis. | pmid:9675458 |
de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
Sanfélix Genovés J et al. | [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. | 1998 | Aten Primaria | pmid:9670578 |
Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
Goh KL et al. | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? | 1997 | Aliment. Pharmacol. Ther. | pmid:9663838 |
Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
Amsden GW et al. | Oral cimetidine prolongs clarithromycin absorption. | 1998 | Antimicrob. Agents Chemother. | pmid:9660986 |
Klein JO | Clarithromycin and azithromycin. | 1998 | Pediatr. Infect. Dis. J. | pmid:9655546 |
Wiedermann BL | Macrolides: clarithromycin and azithromycin. | 1998 | Pediatr Rev | pmid:9654947 |
Moshkowitz M et al. | One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. | 1998 | Pediatrics | pmid:9651466 |
Parente F et al. | Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. | 1998 | Scand. J. Gastroenterol. | pmid:9648983 |
Nakamura T et al. | [Topics on Helicobacter pylori (discussion)]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648442 |
Sato R et al. | [Problems following antibiotic therapy for eradication of Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648440 |
Aoyama N | [Efficacy of antibiotic therapy in eradicating Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648439 |
Kimura K and Sato K | [Recent topics on Helicobacter pylori--Historic background and problems caused by bacteria]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648427 |
Shimoyama T et al. | [Antibiotic therapy in eradicating Helicobacter pylori infections]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648426 |
Wharton JR et al. | Erythrasma treated with single-dose clarithromycin. | 1998 | Arch Dermatol | pmid:9645634 |
Makhani S et al. | Atypical cervico-facial mycobacterial infections in childhood. | 1998 | Br J Oral Maxillofac Surg | pmid:9643597 |
Grove DI et al. | Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. | 1998 | Pathology | pmid:9643503 |
Gray VS | Syncopal episodes associated with cisapride and concurrent drugs. | 1998 | Ann Pharmacother | pmid:9640482 |
Nordt SP et al. | Clarithromycin induced digoxin toxicity. | 1998 | J Accid Emerg Med | pmid:9639187 |
Burman WJ et al. | AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9635911 |
Calvet Calvo X | [Treatment of Helicobacter pylori infections]. | 1998 | Gastroenterol Hepatol | pmid:9633184 |
Miwa H et al. | Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. | 1998 | Helicobacter | pmid:9631313 |
Battaglia G et al. | Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. | 1998 | Helicobacter | pmid:9631310 |
Fireman Z et al. | Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel. | 1998 | Helicobacter | pmid:9631306 |
Domingo D et al. | High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. | 1998 | J. Antimicrob. Chemother. | pmid:9630414 |